ABL Bio Inc. (298380.KQ)
KRW 27400.0
(-5.03%)
KRW 27400.0
(-5.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 86.06 Billion KRW | -25.59% |
| 2022 | 115.66 Billion KRW | 1117.57% |
| 2021 | 9.49 Billion KRW | 2.93% |
| 2020 | 9.22 Billion KRW | -15.28% |
| 2019 | 10.89 Billion KRW | -8.5% |
| 2018 | 11.9 Billion KRW | -88.8% |
| 2017 | 106.32 Billion KRW | 441.66% |
| 2016 | 19.62 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 76.95 Billion KRW | -10.59% |
| 2024 Q2 | 67.55 Billion KRW | -12.21% |
| 2023 Q1 | 106.99 Billion KRW | -7.5% |
| 2023 Q4 | 86.06 Billion KRW | -3.33% |
| 2023 Q3 | 89.02 Billion KRW | -10.97% |
| 2023 Q2 | 99.99 Billion KRW | -6.54% |
| 2023 FY | 86.06 Billion KRW | -25.59% |
| 2022 Q1 | 94.87 Billion KRW | 898.65% |
| 2022 Q4 | 115.66 Billion KRW | 47.28% |
| 2022 Q3 | 78.53 Billion KRW | -13.47% |
| 2022 Q2 | 90.76 Billion KRW | -4.33% |
| 2022 FY | 115.66 Billion KRW | 1117.57% |
| 2021 FY | 9.49 Billion KRW | 2.93% |
| 2021 Q2 | 6.22 Billion KRW | -28.6% |
| 2021 Q4 | 9.49 Billion KRW | 64.51% |
| 2021 Q3 | 5.77 Billion KRW | -7.26% |
| 2021 Q1 | 8.72 Billion KRW | 0.0% |
| 2020 FY | 9.22 Billion KRW | -15.28% |
| 2019 FY | 10.89 Billion KRW | -8.5% |
| 2018 FY | 11.9 Billion KRW | -88.8% |
| 2017 FY | 106.32 Billion KRW | 441.66% |
| 2016 FY | 19.62 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | 109.56 Billion KRW | 21.446% |
| Hyundai Bioscience Co., Ltd. | 7.52 Billion KRW | -1044.371% |
| ST Pharm Co.,Ltd. | 299.92 Billion KRW | 71.304% |
| Cellid, Co., Ltd. | 23.42 Billion KRW | -267.377% |